



VANDERBILT UNIVERSITY

# Macrophage-Targeted Polymer-Drug Conjugates for STING Pathway Activation to Improve Cancer Immunotherapy

Jacqueline E. Anotot<sup>3</sup>, Taylor Sheehy<sup>1</sup>, Karan Arora<sup>2</sup>, John T. Wilson<sup>1,2</sup>


<sup>1</sup>Department of Biomedical Engineering, Vanderbilt University; <sup>2</sup>Department of Chemical and Biomolecular Engineering, Vanderbilt University; <sup>3</sup>George & Josephine Butler Polymer Research Laboratory, Center for Macromolecular Science & Engineering, Department of Chemistry, University of Florida



UNIVERSITY of FLORIDA


## Background

### The Cancer Immunity Cycle (CIC)



**Figure 1:** Cancer remains the second leading cause of death nationwide. One promising approach to combat cancer is by modulating the cancer immunity cycle, which outlines the series of steps the immune system undergoes to recognize and eliminate cancer cells. The CIC serves as a framework for developing novel immunotherapies that harness and enhance the immune response to target and eliminate cancer more effectively.


### STING Signaling to Promote the CIC




**Figure 2:** The Stimulator of Interferon Genes (STING) pathway is a cellular signaling pathway that detects the presence of cytosolic DNA, including DNA released by cancer cells. Activation of STING triggers the production of immune-stimulating molecules and enhances various aspects of the cancer immunity cycle. Due to the crucial role of STING in antitumor immunity, STING pathway agonists are being developed as next-generation cancer immunotherapeutics to activate this pathway and enhance the anti-tumor immune response.

## In Vitro Macrophage Polarization and Uptake


### Macrophage Polarization




**Figure 5:** M0 macrophage polarization to M1 and M2 phenotypes using stimuli factors



**Figure 6:** RAWs exhibit M1 polarization, characterized by CD86 detection marker expression and M2 polarization, marked by CD206 detection





**Figure 7:** Bone Marrow-Derived Macrophages (BMDMs) Extraction and Polarization




**Figure 8:** BMDMs exhibit M1 polarization, characterized by CD86 detection marker expression, and M2 polarization, marked by CD206 detection

### Polymer Uptake Study





**Figure 9:** In vitro understanding of preferential uptake by M2 BMDMs with Cy5-labeled, mannose-functionalized platforms and non-functionalized platform. Read out: Flow cytometry looking at % Cy5-positive cells.



**Figure 10:** In vitro understanding of preferential uptake by M2 RAWs with Cy5-labeled, mannose-functionalized platforms and non-functionalized platform. Read out: Flow cytometry looking at % Cy5-positive cells.

## Polymer Biodistribution

### Polymer Biodistribution



**Figure 11:** 15% Mannose functionalized vs non functionalized polymer carrier were labeled with a Cy5 dye and systemically injected into mice. At 24 hours, organs were harvested, and organ fluorescence was measured via IVIS. Increased uptake in the spleen can be visualized with the mannose-functionalized carrier.

## Conclusions and Future Directions

### Conclusions

- We successfully synthesized poly(N,N-dimethylacrylamide-co-Azide ethylmethacrylate-co-Mannose) terpolymers via RAFT Polymerization
- We polarized both BMDMs and RAWs to M1 and M2 phenotypes
- Macrophage uptake may increase with increasing mannose density
- Targeted polymer accumulates in macrophage-rich organs

### Future Directions

- Conjugation of STING prodrug to our lead polymer carrier via copper-free click chemistry and characterize via UV-Vis
- Measure STING activation in M2 macrophages via IFN ELISA comparing mannose-functionalized vs non-functionalized platform
- Measure the ability of the mannose platform to repolarize M2 macrophages towards an M1 phenotype
- Biodistribution and therapeutic efficacy of targeted vs non targeted platforms using E0771 murine tumor model

## Acknowledgements




Wilson Lab, Vanderbilt University  
Karan Arora, Vijaya Bharti, Youn Jae Jung, Blaise Kimmel, Alex Kwiatkowski, Taylor Sheehy, Hayden Pagendarm, Lucinda Pastora, Jacob Schulman, Rachael Smith, Payton Stone

Research for this project was funded by the National Science Foundation under grant number NSF-DMR 1852157.

Special thanks to Taylor Sheehy, Dr. Wilson, and the VINSE community



## Polymer Delivery Technologies



### Advantages of Drug Conjugation to a Polymer Carrier:

- Drug solubilization
- Improved pharmacokinetics
- Tumor targeting
- Reduced systemic toxicity
- Environmentally-responsive drug release


## Polymeric Carrier Design

DMA is a water-soluble and biocompatible monomer that will solubilize the STING prodrug


AzEMA allows for chemical conjugation to the DBCO reactive handle on the STING prodrug

Mannose is the biological moiety that targets tumor associated macrophages (TAMs)

Deprotected mannose is readily recognized by mannose receptors present on TAMs



**Figure 3:** Synthesis of 100kDa poly(N,N-dimethylacrylamide-co-Azide ethylmethacrylate-co-Mannose) terpolymers via Reversible Addition-Fragmentation Chain Transfer (RAFT) polymerization



**Figure 4:** Mannose deprotection in sodium methoxide for 100kDa poly(N,N-dimethylacrylamide-co-Azide ethylmethacrylate-co-Mannose) terpolymers to increase cellular uptake

Mannose (%)	AzEMA (%)	DMA (%)
0	10	90
5	10	85
15	10	75
30	10	60